We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
Overcoming Oligonucleotide Manufacturing Challenges
24 Mar 2023 - The Oligonucleotide CMO industry faces a number of challenges – Demand out pacing capacity for manufacturing, available expertise, high solvent and waste usage to name a […]
Read moreChemical strategies in extending half-lives of therapeutic peptides
24 Mar 2023 - Therapeutic peptides have been proven to be very effective in treating critical human diseases. Their number on the pharmaceutical market has significantly increased over the past […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2023
22 Mar 2023 - Baar, 22 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (the “Company”), published today the […]
Read morePolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023
14 Mar 2023 - Baar, 14 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its results for […]
Read moreCEO of PolyPeptide resigns
30 Jan 2023 - Baar, 30 January 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the resignation by […]
Read morePolyPeptide signs significant commercial agreement
19 Dec 2022 - Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a […]
Read morePolyPeptide provides market update
2 Dec 2022 - Baar, 2 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today provided a market update. […]
Read moreFluoGuide reaches milestone with FG001 for phase III clinical supply
9 Nov 2022 - “We are thankful for the opportunity to work with FluoGuide on the highly innovative FG001 project and congratulate the whole team for reaching this milestone.”
Read moreFrom 10 grams to several hundred – A case study in peptide GMP process development
17 Oct 2022 - Presentation from TIDES digital week, September 2022, by Niall McLoughlin, PhD, Development Project Chemist at PolyPeptide Group.[…]
Read more